Literature DB >> 21716820

Wegener's granulomatosis confined to nervous system.

M Lucchetta1, M Favero, F Schiavon, A Cagnin, R Manara, A Rotilio, E Orvieto, C Giannini, C Briani.   

Abstract

Wegener's granulomatosis (WG) is a multisystemic necrotising granulomatous vasculitis of small and medium sized vessels, that primarily involves the upper and lower respiratory tracts, lung tissues and kidneys. Serum antineutrophil cytoplasmic antibodies (ANCA) are a sensitive and specific marker of WG. Whereas the peripheral nervous system is often involved in WG, central nervous system manifestations are reported only in 2-8%, and are rarely present at onset. We report on a patient with atypical neurological presentation of ANCA negative WG in whom the diagnosis was made only after a meningeal biopsy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 21716820      PMCID: PMC3124743          DOI: 10.1136/bcr.06.2008.0283

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  4 in total

1.  Limited prognostic value of changes in antineutrophil cytoplasmic antibody titer in patients with Wegener's granulomatosis.

Authors:  G S Kerr; T A Fleisher; C W Hallahan; R Y Leavitt; A S Fauci; G S Hoffman
Journal:  Arthritis Rheum       Date:  1993-03

2.  Neurological involvement in Wegener's granulomatosis: an analysis of 324 consecutive patients at the Mayo Clinic.

Authors:  H Nishino; F A Rubino; R A DeRemee; J W Swanson; J E Parisi
Journal:  Ann Neurol       Date:  1993-01       Impact factor: 10.422

3.  Wegener granulomatosis: an analysis of 158 patients.

Authors:  G S Hoffman; G S Kerr; R Y Leavitt; C W Hallahan; R S Lebovics; W D Travis; M Rottem; A S Fauci
Journal:  Ann Intern Med       Date:  1992-03-15       Impact factor: 25.391

4.  Severe dysphagia in lower cranial nerve involvement as the initial symptom of Wegener's granulomatosis.

Authors:  Mario Armani; Marco Spinazzi; Cinzia Andrigo; Ambrogio Fassina; Mauro Mantovan; Bruno Tavolato
Journal:  J Neurol Sci       Date:  2007-07-20       Impact factor: 3.181

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.